Fortis Therapeutics
Fortis Therapeutics is an immuno-oncology biotechnology company focused on the discovery and development of antibody-drug conjugate therapies that target the transmembrane immune modulatory receptor CD46. The company develops tumor-selective antibodies identified using tumor cell–based selection methods, conjugates them to cytotoxic payloads via established chemistry platforms, and advances candidates through preclinical studies and Phase 1 clinical trials. Fortis was founded on technology licensed from an academic laboratory and has executed multiple series A financings to support clinical development.
Industries
Nr. of Employees
small (1-50)
Fortis Therapeutics
La Jolla, California, United States, North America
Patents
Engineered CD46-specific effector cells and uses thereof in the treatment of cancer
US-12049511-B2
View Details
Engineered CD46-specific effector cells and uses thereof in the treatment of cancer
US-12049511-B2
View DetailsProducts
Antibody-drug conjugate targeting CD46 (lead clinical candidate)
A fully human antibody recognizing a tumor-specific epitope on the immune modulatory receptor CD46, conjugated to a cytotoxic payload; advanced through preclinical testing and into Phase 1 clinical trials for late-stage prostate cancer and multiple myeloma.
FOR46
FOR46 is an antibody-drug conjugate targeting CD46, designed to recognize a tumor-specific epitope on CD46 and deliver a potent payload to kill tumor cells.
Antibody-drug conjugate targeting CD46 (lead clinical candidate)
A fully human antibody recognizing a tumor-specific epitope on the immune modulatory receptor CD46, conjugated to a cytotoxic payload; advanced through preclinical testing and into Phase 1 clinical trials for late-stage prostate cancer and multiple myeloma.
FOR46
FOR46 is an antibody-drug conjugate targeting CD46, designed to recognize a tumor-specific epitope on CD46 and deliver a potent payload to kill tumor cells.
Services
Partnered preclinical and translational projects with academic and philanthropic organizations to support target validation and clinical translation.
Partnered preclinical and translational projects with academic and philanthropic organizations to support target validation and clinical translation.
Expertise Areas
- Antibody-drug conjugate development
- Immuno-oncology
- Preclinical efficacy and safety evaluation
- Phase 1 clinical trial management
Key Technologies
- Antibody-drug conjugates (ADCs)
- Tumor cell–based antibody selection (in situ/tissue microenvironment)
- Payload conjugation chemistry
- In vitro cytotoxicity assays
News & Updates
Announcement of a $40 million financing to advance the company's CD46-targeting ADC into clinical trials for multiple myeloma and metastatic castration-resistant prostate cancer.
Announcement of an $18 million Series A financing to support development of antibody-drug conjugate therapies for late-stage cancers.
Announcement that the FDA cleared two IND applications for the company's lead ADC program to treat metastatic castration-resistant prostate cancer and late-stage multiple myeloma.
Two investigational new drug applications cleared by the U.S. FDA enabling clinical trials in prostate cancer and multiple myeloma.
Multiple series A financings announced to fund clinical development (notably $18M and $40M rounds).
Announcement of a $40 million financing to advance the company's CD46-targeting ADC into clinical trials for multiple myeloma and metastatic castration-resistant prostate cancer.
Announcement of an $18 million Series A financing to support development of antibody-drug conjugate therapies for late-stage cancers.
Announcement that the FDA cleared two IND applications for the company's lead ADC program to treat metastatic castration-resistant prostate cancer and late-stage multiple myeloma.
Two investigational new drug applications cleared by the U.S. FDA enabling clinical trials in prostate cancer and multiple myeloma.
Multiple series A financings announced to fund clinical development (notably $18M and $40M rounds).